Elite Pharmaceuticals Inc (ELTP): EBITDA
$50.18M
Year ended 2026-03-31
$35.99M
Trailing 12 months to 2026-06-30
+116.4%
3-year compound annual growth
+71.1%
5-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $50.18M | +141.0% | 2026-06-29, From 2025-04-01 |
| 2025-03-31 | $20.83M | +72.0% | 2026-06-29, From 2024-04-01 |
| 2024-03-31 | $12.11M | +144.5% | 2025-06-30, From 2023-04-01 |
| 2023-03-31 | $4.95M | -21.1% | 2024-07-01, From 2022-04-01 |
| 2022-03-31 | $6.28M | +83.7% | 2023-06-29, From 2021-04-01 |
| 2021-03-31 | $3.42M | n/m | 2022-06-29, From 2020-04-01 |
| 2020-03-31 | -$965.6K | n/m | 2021-06-14, From 2019-04-01 |
| 2019-03-31 | -$7.90M | n/m | 2020-06-29, From 2018-04-01 |
| 2018-03-31 | -$8.05M | n/m | 2019-06-21, From 2017-04-01 |
| 2017-03-31 | -$6.64M | n/m | 2018-06-14, From 2016-04-01 |
| 2016-03-31 | -$7.65M | n/m | 2018-06-14, From 2015-04-01 |
| 2015-03-31 | -$15.93M | n/m | 2017-06-14, From 2014-04-01 |
| 2014-03-31 | -$4.83M | n/m | 2016-06-15, From 2013-04-01 |
| 2013-03-31 | -$1.14M | n/m | 2014-06-30, From 2012-04-01 |
| 2012-03-31 | -$1.48M | n/m | 2013-06-21, From 2011-04-01 |
| 2011-03-31 | -$402.3K | n/a | 2012-06-29, From 2010-04-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $50.18M | +141.0% |
| Macrogenics Inc (MGNX) | 2025-12-31 | -$65.67M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$224.0K | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$49.85M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$9.22M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$159.35M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$9.09M | n/m |
| Xencor Inc (XNCR) | 2025-12-31 | -$166.99M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $8.87M | -42.2% |
Compare ELTP, MGNX, HRTX, LQDA side by side · Screen every company in Pharmaceutical Preparations ↗